Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
4.600
-0.010 (-0.22%)
At close: May 12, 2025, 4:00 PM
4.600
0.00 (0.00%)
After-hours: May 12, 2025, 6:11 PM EDT
Amylyx Pharmaceuticals Revenue
Amylyx Pharmaceuticals had revenue of $-1.27M in the twelve months ending March 31, 2025, down -100.32% year-over-year. In the year 2024, Amylyx Pharmaceuticals had annual revenue of $87.37M, down -77.06%.
Revenue (ttm)
$-1.27M
Revenue Growth
-100.32%
P/S Ratio
-320.42
Revenue / Employee
n/a
Employees
123
Market Cap
407.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AMLX News
- 20 hours ago - Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome - Business Wire
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Accesswire
- 2 days ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - Accesswire
- 4 days ago - Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results - Business Wire
- 5 days ago - Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences - Business Wire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - Accesswire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out - Accesswire